Research programme: Parkinson's disease diagnostics and therapeutics - BPG Bio/Parkinson's Institute and Clinical Center
Latest Information Update: 26 Aug 2025
At a glance
- Originator Berg Pharma; The Parkinsons Institute and Clinical Center
- Developer BPG Bio; The Parkinsons Institute and Clinical Center
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 26 Aug 2025 Discontinued - Preclinical for Parkinson's disease (Diagnosis) in USA (unspecified route) (BPG Bio pipeline, August 2025)
- 26 Aug 2025 Discontinued for Parkinson's disease in USA (unspecified route) before August 2025 (BPG Bio pipeline, August 2025)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Parkinson's-disease(Diagnosis) in USA